|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
1994-2-24
|
|
pubmed:abstractText |
The proper evaluation of new forms of technology depends on the results of clinical trials. However, the treatment of patients in grant-sponsored clinical trials of cancer therapy usually requires that the proposed treatment be approved in advance by an insurance carrier in a process called predetermination.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0028-4793
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
17
|
|
pubmed:volume |
330
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
473-7
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:8289855-Antineoplastic Agents,
pubmed-meshheading:8289855-Bone Marrow Transplantation,
pubmed-meshheading:8289855-Breast Neoplasms,
pubmed-meshheading:8289855-Cancer Care Facilities,
pubmed-meshheading:8289855-Clinical Trials as Topic,
pubmed-meshheading:8289855-Cost-Benefit Analysis,
pubmed-meshheading:8289855-Eligibility Determination,
pubmed-meshheading:8289855-Female,
pubmed-meshheading:8289855-Hospitals, University,
pubmed-meshheading:8289855-Humans,
pubmed-meshheading:8289855-Insurance Claim Review,
pubmed-meshheading:8289855-North Carolina,
pubmed-meshheading:8289855-Prospective Studies,
pubmed-meshheading:8289855-Remission Induction
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
Variation in approval by insurance companies of coverage for autologous bone marrow transplantation for breast cancer.
|
|
pubmed:affiliation |
Duke University Bone Marrow Transplant Program, Duke Comprehensive Cancer Center, Durham, NC 27710.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial
|
